Genentech's goal is to deliver new treatment options to patients with serious or life-threatening medical conditions. Since its founding in 1976, the company's research organization has focused its drug discovery efforts on therapies that would fill unmet needs, and Genentech has brought multiple novel biotherapeutics to market in the areas of oncology, immunology, and disorders of tissue growth and repair. As part of the merger with Roche in March 2009, Genentech became the headquarters for all Roche pharmaceutical operations in the United States, and products that were previously marketed by Roche are now being marketed by Genentech in the United States. The combined portfolio of medicines is one of the most impressive in the industry.

For 20 years, Genentech has been committed to making sure price is not a barrier to access for patients. For those who do not have insurance or who need assistance with co-payments or reimbursement, Genentech supports several programs for eligible patients treated for approved indications in the United States. Read about Genentech's various patient access programs and donations.